

## Report on the Activities of the EORTC-NCI Exchange Program

THE EXCHANGE PROGRAM originated in an agreement between the EORTC and the U.S. National Cancer Institute signed in April 1985 by virtue of which research scholars with at least three years of postdoctoral research may apply for an EORTC-NCI fellowship to do fundamental cancer research in laboratories in the U.S.A. or in Europe. Details of the Exchange Program, qualifications of the candidates and instructions for application are given in the *European Journal of Cancer & Clinical Oncology* (1985, **21**, 995-997 and 1986, **22**, 537-538) and the *EORTC Newsletter* (No. 129, April 1985). Additional information if needed and application forms should be obtained from the Brussels office for the EORTC-NCI Exchange Program.

We are reporting that appointments of candidates began in June, 1985 with the following exchanges from Europe and Israel to the U.S.A.

Of the 72 eligible candidates who have submitted applications since June, 1985, 36 have been selected, from the following countries:

Belgium	3
Denmark	2
Finland	1
France	8
Israel	4
Italy	9
Netherlands	3
Norway	1
Spain	1
Sweden	1
U.K.	1
U.S.A.	1
West Germany	1.

These candidates are distributed as follows:

<i>Country</i>	<i>Name</i>	<i>Host laboratory</i>
Belgium	J.L. Canon	Dr. Frei, Harvard University
	A.M. Lebacqz	Dr. Minna, NCI
	Z. Berncman	Dr. Gallo, NCI
Denmark	N. Brünnner	Dr. Lippman, NCI
	S. Thorpe	Dr. Schimke, Stanford, CA
Finland	A. Ranki*	Dr. Gallo, NCI
France	H. Richard-Foy*	Dr. Thorgeirsson, NCI
	L. Bich-Thuy*	Dr. Queen, NCI
	J. Markovits*	Dr. Kohn, NCI
	B. Coudert*	Dr. Boyd, NCI
	F. Thomas	Dr. Minna, NCI
	M. Lipinski	Dr. Israel, NCI
	M. Mezzina	Dr. Friedberg, Stanford, CA
	F. Thierry	Dr. Howley, NCI

\*Successfully completed.

<i>Country</i>	<i>Name</i>	<i>Host laboratory</i>
Israel	R. Catane*	Dr. Herberman, NCI
	C. Webb*	Dr. Karin, University of California at La Jolla
	E. Heller*	Dr. Gallo, NCI
	Y. Sharoni	Dr. Minna, NCI
Italy	A. Migliaccio	Dr. Aaronson, NCI
	E. Vicenzi*	Dr. Sporn, NCI
	R. Favoni	Dr. Lippman, NCI
	L. Languino	Dr. Ruoslahti, La Jolla Cancer Research Foundation, CA
	C. Tondini	Dr. Kufe, Dana Farber, Boston, MA.
	G. Capranico	Dr. Kohn, NCI
	R. Danesi	Dr. Myers, NCI
	G. Giaccone	Dr. Gazdar, NCI
	F. Giancotti	Dr. Ruoslahti, La Jolla, CA
Netherlands	S. de Graaf	Prof. Evans, Tennessee
	P. Speth*	Dr. Collins, NCI
	P. Roholl	Dr. Baird, San Diego, CA
Norway	K. Skarstad	Dr. Kornberg, Stanford, CA
Spain	R. Colomer	Dr. Gelmann, NCI
Sweden	P. Biberfeld*	Dr. Gallo, NCI
U.K.	K. Elliott*	Dr. Oppenheim, NCI
U.S.A.	B. Foster	Dr. Calvert, Sutton, Surrey
West Germany	H.J. Schütte	Dr. Minna, NCI

Of the 36 selected fellows there were 23 men and 13 women. They were 29–59 years old with a mean age of 37 years.

All candidates have completed three years of research related to oncology at the time they left for the U.S.A.; all had been accepted in specific laboratories of interest to them and all were assured that they would be welcomed back by their former employers after their American experience.

Selected fellows receive one half of their stipend from a European source, most often their home institution or a European foundation as arranged by EORTC; the other half is provided by NCI.

Dr. Ihor Masnyk, director of international affairs NCI and Dr. Omar Yoder of the NCI Liaison Office in Brussels have executive responsibilities in this program in collaboration with the selection committee of the EORTC. Mrs. Moore-Deflandre, Honorary Secretary General of the Commission for Educational Exchange between the U.S.A. and Belgium has been instrumental in securing the

support of the different commissions in Europe for travel expenses of the fellows.

It is expected that this program will continue and could probably be expanded in view of the enthusiastic reception on both sides of the Atlantic.

The EORTC Selection Committee is considering additional candidates, from all member countries and from the U.S.A., for it is a part of the agreement that qualified American researchers recommended by NCI should also be assigned to EORTC approved laboratories.

Candidates are invited to apply in time for the Exchange competition which takes place on April 15 and November 15 each year. Applications should be received as soon as possible before the deadlines in order to allow processing by the Selection Committee.

Mrs A.M. STIFT  
Executive Secretary

H.J. TAGNON, M.D.,  
Chairman,  
Selection Committee

\*Successfully completed.

**DISTRIBUTION OF FELLOWS BY HOME INSTITUTION**

Belgium	Catholic University of Louvain	A.M. Lebacqz J.L. Canon Z. Berneman
	University Hospital of Antwerp	
Denmark	Copenhagen University Hospital	N. Brünner S. Thorpe
Finland	Helsinki University	A.M. Ranki
France	INSERM, Paris	L.T. Bich-Thuy H. Richard-Foy
	C.H.U. Dijon	B. Coudert
	Gustave Roussy, Villejuif	J. Markovits F. Thomas M. Lipinski M. Mezzina F. Thierry
	Institut Pasteur, Paris	
	Hadassah Hospital, Jerusalem	R. Catane E. Heller Y. Sharoni C. Webb
	Ben Gurion University, Beer-Sheva Weizmann Institute, Rehovot	
Italy	Istituto Nazionale, Genova Mario Negri, Milan	R. Favoni L. Languino E. Vicenzi A.R. Migliaccio C. Tondini G. Capranico R. Danesi G. Giaccone F. Giancotti
	Istituto Sanita, Roma Istituto Tumori, Milan	
	University of Pisa Istituto San Giovanni, Torino University of Torino	
	University Hospital Groningen St. Radboud Hospital, Nijmegen Institute of Pathology, Utrecht	S. de Graaf P. Speth P. Roholl
Norway	Norwegian Radium Hospital, Oslo	K. Skarstad
Spain	Madrid Hospital	R. Colomer
Sweden	Karolinska Institute, Stockholm	P. Biberfeld
U.K.	University of Manchester	K. Elliott
U.S.A.	NCI, Bethesda, MD	B. Foster
West Germany	Klinikum Essen	H.J. Schütte

**DISTRIBUTION OF FELLOWS BY HOST INSTITUTION IN THE U.S.A.***1. National Cancer Institute, N.I.H., Bethesda, MD*

Tumor Cell Biology Laboratory (R.G. Gallo)	P. Biberfeld (Sweden) A.M. Ranki (Finland) E. Heller (Israel) Z. Berneman (Belgium)
Laboratory of Biochemistry (M.F. Singer)	L.T. Bich Thuy (France)
Breast Cancer Section (M.E. Lippman)	N. Brünner (Denmark) R. Favoni (Italy)
Laboratory of Biological Modifiers (D. Longo)	R. Catane (Israel)

Laboratory of Biological Response Modifiers (J.J. Oppenheim, Frederick, M.D.)	K. Elliott (U.K.)
Laboratory of Developmental Therapeutics (M.R. Boyd)	B. Coudert (France)
Medical Oncology (NCI-Navy) (J.D. Minna)	A.M. Lebacqz (Belgium) H.J. Schütte (West Germany) Y. Sharoni (Israel) F. Thomas (France)
Laboratory of Molecular Pharmacology (K.W. Kohn)	J. Markovits (France) G. Capranico (Italy)
Laboratory of Cellular Molecular Biology (S.A. Aaronson)	A.R. Migliaccio (Italy)
Laboratory of Experimental Carcinogenesis (S.S. Thorgeirsson)	H. Richard-Foy (France)
Pharmacokinetics Section, Clinical Pharmacology Branch (J.M. Collins)	P. Speth (Netherlands)
Laboratory of Chemoprevention (M.B. Sporn)	E. Vicenzi (Italy)
Department of Medicine (Dr. Gelmann)	R. Colomer (Spain)
Department of Clinical Pharmacology (Dr. Myers)	R. Danesi (Italy)
Navy Medical Oncology (Dr. Gazdar)	G. Giaccone (Italy)
Molecular Genetics, Pediatrics (Dr. Israel)	M. Lipinski (France)
Tumor Virus Biology (Dr. Howley)	F. Thierry (France)
2. <i>Dana Farber Institute, Boston MA</i>	
Medicine (E. Frei)	J.L. Canon (Belgium)
Medical Oncology (D.W. Kufe)	C. Tondini (Italy)
3. <i>St. Jude's Childrens Research Hospital, Memphis, TN</i>	
Pharmaceutical Division (W.E. Evans)	S. de Graaf (Netherlands)
4. <i>La Jolla Cancer Research Foundation, La Jolla, CA</i>	
Molecular Pharmacology (E. Ruoslahti)	L. Languino (Italy) F. Giancotti (Italy)
E.D. Adamson	C. Webb (Israel)
5. <i>Stanford University, Stanford, CA</i>	
Biological Sciences (Dr. Schimke)	S. Thorpe (Denmark)
Laboratory of Experimental Oncology (E.C. Friedberg)	M. Mezzina (France)
Department of Biochemistry (A. Kornberg)	K. Skarstad (Norway)
6. <i>Salk Institute, San Diego CA</i> (Dr. Baird)	
	P. Roholl (Netherlands)
7. <i>Institute of Cancer Research, Sutton, Surrey, U.K.</i> (H. Calvert)	
	B. Foster (U.S.A.)